A rare cancer-fighting plant compound has been decoded – Image for illustrative purposes only (Image credits: Pixabay)
Researchers at UBC Okanagan have identified the precise biological machinery that allows certain tropical plants to assemble mitraphylline, a scarce natural compound long noted for its anti-cancer potential. The finding resolves a decades-old question about how the molecule acquires its distinctive twisted shape. With mitraphylline occurring only in trace quantities in plants such as kratom and cat’s claw, the discovery points toward more reliable methods of obtaining it without relying on limited wild harvests.
A Longstanding Puzzle in Plant Chemistry
Plant biologists have known for years that mitraphylline belongs to a family of alkaloids with intriguing biological activity. Yet the sequence of reactions that builds the compound inside living cells remained unknown. The UBC Okanagan team focused on two enzymes that appear to act in concert, each performing a specific chemical step that the other cannot complete alone. Their combined action produces the final structure that gives mitraphylline its unusual three-dimensional form.
Because the enzymes operate only in a narrow set of tropical species, the compound has remained difficult to study in meaningful quantities. The new work shows exactly which genes encode these enzymes and how their protein products interact during the final stages of synthesis. This level of detail had been missing from earlier attempts to understand the pathway.
From Tiny Amounts to Potential Scale
Traditional extraction from plant material yields only minute quantities of mitraphylline, limiting both laboratory testing and any future therapeutic exploration. The identification of the two key enzymes opens the possibility of transferring the pathway into faster-growing organisms or engineered cell cultures. Such approaches have already succeeded with other complex plant molecules used in medicine.
The researchers emphasize that the enzymes alone do not guarantee large-scale production. Additional regulatory steps and cellular conditions still need to be mapped before reliable manufacturing becomes feasible. Even so, the current breakthrough removes the primary barrier that had blocked progress for so long.
What the Enzymes Reveal
One enzyme appears to create an intermediate structure, while the second enzyme folds that intermediate into the final twisted configuration characteristic of mitraphylline. This two-step cooperation explains why the molecule had resisted earlier efforts at chemical synthesis or genetic reconstruction. The discovery also highlights how plants can evolve highly specific enzyme pairs to generate rare secondary metabolites.
Understanding this partnership may help scientists recognize similar patterns in other medicinal plants. It could accelerate the search for additional compounds that share the same structural features and biological promise. At present, however, the work remains focused on mitraphylline itself.
Next Steps and Open Questions
The UBC Okanagan group plans to test whether the identified enzymes can function outside their native plant cells. Early experiments will likely involve introducing the genes into model organisms to observe whether mitraphylline can be produced in measurable amounts. Success here would mark the first practical step toward sustainable sourcing.
Broader questions remain about how the plant regulates these enzymes and whether environmental factors influence their activity. Answering those questions will determine how readily the pathway can be scaled or optimized. For now, the decoded mechanism stands as a clear advance in the effort to harness a rare natural product with demonstrated anti-cancer properties.